CO6251325A2 - Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr) - Google Patents

Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)

Info

Publication number
CO6251325A2
CO6251325A2 CO09144825A CO09144825A CO6251325A2 CO 6251325 A2 CO6251325 A2 CO 6251325A2 CO 09144825 A CO09144825 A CO 09144825A CO 09144825 A CO09144825 A CO 09144825A CO 6251325 A2 CO6251325 A2 CO 6251325A2
Authority
CO
Colombia
Prior art keywords
seq
human
variable region
sequence
chain variable
Prior art date
Application number
CO09144825A
Other languages
English (en)
Inventor
Liqun Dong
Marc Nasoff
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of CO6251325A2 publication Critical patent/CO6251325A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1.- Un anticuerpo aislado o una porción de enlace de antígeno del mismo, el cual comprende una secuencia de la región variable de cadena pesada de la SEQ ID NO: 7 o de la SEQ ID NO: 21. 2.- Un anticuerpo aislado o una porción de enlace de antígeno del mismo, el cual comprende una secuencia de la región variable de cadena pesada de la SEQ ID NO: 7, y una secuencia de la región variable de cadena ligera de la SEQ ID NO: 8, o una secuencia de la región variable de cadena pesada de la SEQ ID NO: 21, y una secuencia de la región variable de cadena ligera de la SEQ ID NO: 22. 3.- El anticuerpo de la reivindicación 2, el cual comprende CDRH1, H2 y H3 de las SEQ ID NOs: 1, 2, y 3, respectivamente, o de las SEQ ID NOs: 15, 16, y 17, respectivamente, o una secuencia de CDRL1, L2 y L3 de las SEQ ID NOs: 4, 5, y 6, respectivamente, o de las SEQ ID NOs: 18, 19, y 20, respectivamente. 4.- El anticuerpo de la reivindicación 2, el cual comprende las CDRH1, H2 y H3 de las SEQ ID Nos: 1, 2, y 3, respectivamente, o de las SEQ ID Nos: 15, 16, y 17, respectivamente, y una secuencia de CDRL1, L2, y L3 de las SEQ ID NOs: 4, 5, y 6, respectivamente, o de las SEQ ID NO: 18, 19, y 20, respectivamente. 5.- El anticuerpo de la reivindicación 2, el cual comprende una secuencia de aminoácidos de la región variable de cadena pesada que es cuando menos el 80 por ciento idéntica a la SEQ ID NO: 7, y una secuencia de aminoácidos de la región variable de cadena ligera que es cuando menos el 80 por ciento idéntica a la SEQ ID NO: 8, o que comprende una secuencia de aminoácidos de la región variable de cadena pesada que es cuando menos el 80 por ciento idéntica a la SEQ ID NO: 21, y una secuencia de aminoácidos de la región variable de cadena ligera que es cuando menos el 80 por ciento idéntica a la SEQ ID NO: 22. 6.- El anticuerpo de la reivindicación 2, el cual es un anticuerpo quimérico.
CO09144825A 2007-06-20 2009-12-17 Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr) CO6251325A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94520507P 2007-06-20 2007-06-20

Publications (1)

Publication Number Publication Date
CO6251325A2 true CO6251325A2 (es) 2011-02-21

Family

ID=39846944

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09144825A CO6251325A2 (es) 2007-06-20 2009-12-17 Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)

Country Status (20)

Country Link
US (1) US8101182B2 (es)
EP (1) EP2170957A1 (es)
JP (1) JP2010530233A (es)
KR (1) KR20100034015A (es)
CN (1) CN102027012A (es)
AR (1) AR067045A1 (es)
AU (1) AU2008265128A1 (es)
BR (1) BRPI0813725A2 (es)
CA (1) CA2691157A1 (es)
CL (1) CL2008001826A1 (es)
CO (1) CO6251325A2 (es)
CR (1) CR11152A (es)
EA (1) EA201000006A1 (es)
EC (1) ECSP099812A (es)
IL (1) IL202573A0 (es)
PE (1) PE20090768A1 (es)
TN (1) TN2009000529A1 (es)
TW (1) TW200918557A (es)
WO (1) WO2008155365A1 (es)
ZA (1) ZA200908711B (es)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1129190E (pt) 1998-11-13 2007-08-08 Immunex Corp Adn e polipéptidos de tslp humanos.
US7288633B2 (en) 2001-07-23 2007-10-30 Immunex Corporation Modified human thymic stromal lymphopoietin
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
WO2009100324A1 (en) * 2008-02-07 2009-08-13 Schering Corporation Engineered anti-tslpr antibodies
TW201201840A (en) * 2010-07-15 2012-01-16 Hoffmann La Roche Antibodies specifically binding to human TSLPR and methods of use
KR101221649B1 (ko) * 2010-11-01 2013-01-14 광주과학기술원 알러지 질환의 예방 또는 치료용 약제학적 조성물, 그의 스크리닝 방법
RU2689528C2 (ru) * 2013-08-09 2019-05-28 Астеллас Фарма Инк. Новое антитело к tslp-рецептору человека
JP6640113B2 (ja) 2014-05-07 2020-02-05 アムジエン・インコーポレーテツド 衝撃低減要素を有する自動注入器
JP6671298B2 (ja) 2014-05-16 2020-03-25 アムジェン インコーポレイテッド Th1及びth2細胞集団を検出するためのアッセイ
CA2949846C (en) 2014-06-03 2023-09-05 Amgen Inc. Devices and methods for assisting a user of a drug delivery device
MX2021014323A (es) 2014-10-14 2023-02-02 Amgen Inc Dispositivo de inyección de fármaco con indicadores visuales y audibles.
AU2015335743B2 (en) 2014-10-23 2020-12-24 Amgen Inc. Reducing viscosity of pharmaceutical formulations
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
CA2976935C (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
US11806509B2 (en) 2015-02-27 2023-11-07 Amgen Inc. Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
AU2016320748B2 (en) 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
EP3347377B1 (en) 2015-09-09 2021-02-17 Novartis AG Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
CN108430507B (zh) 2015-12-18 2022-08-02 安斯泰来制药株式会社 含有抗人tslp受体抗体的药物组合物
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
WO2017160799A1 (en) 2016-03-15 2017-09-21 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
JP7309363B2 (ja) 2016-05-13 2023-07-18 アムジエン・インコーポレーテツド バイアル・スリーブ組立体
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
EP3465124A1 (en) 2016-06-03 2019-04-10 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
JP2020503976A (ja) 2017-01-17 2020-02-06 アムジエン・インコーポレーテツド 注入デバイスならびに関連する使用および組立方法
WO2018151890A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
JP7280189B2 (ja) 2017-02-17 2023-05-23 アムジエン・インコーポレーテツド 薬物送達装置用の挿入機構
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
US11571511B2 (en) 2017-03-07 2023-02-07 Amgen Inc. Insertion mechanism and method of inserting a needle of a drug delivery device
WO2018165499A1 (en) 2017-03-09 2018-09-13 Amgen Inc. Insertion mechanism for drug delivery device
CA3052676A1 (en) 2017-03-28 2018-10-04 Amgen Inc. Plunger rod and syringe assembly system and method
US20200048367A1 (en) 2017-04-28 2020-02-13 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
CN110709121B (zh) 2017-06-08 2022-06-24 安进公司 扭矩驱动式药物递送装置
MA49447A (fr) 2017-06-22 2020-04-29 Amgen Inc Réduction des impacts/chocs d'activation d'un dispositif
EP3641861A1 (en) 2017-06-23 2020-04-29 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM
MA49626A (fr) 2017-07-21 2020-05-27 Amgen Inc Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
MA49676A (fr) 2017-07-25 2020-06-03 Amgen Inc Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
EP3662288B1 (en) 2017-08-01 2024-02-28 Amgen Inc. Systems and methods for performing a real-time glycan assay of a sample
MA49757A (fr) 2017-08-01 2020-06-10 Amgen Inc Systèmes et procédés de préparation en temps réel d'un échantillon de polypeptide pour analyse par spectrométrie de masse
EP3664863A2 (en) 2017-08-09 2020-06-17 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
IL272636B1 (en) 2017-10-06 2024-06-01 Amgen Inc Drug delivery device with combination assembly and related assembly method
EP3694578A1 (en) 2017-10-09 2020-08-19 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
US11826480B2 (en) 2017-11-03 2023-11-28 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
US20200338271A1 (en) 2017-11-06 2020-10-29 Amgen Inc. Fill-finish assemblies and related methods
CA3079197A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
CN116832271A (zh) 2017-11-10 2023-10-03 安进公司 用于药物递送装置的柱塞
CA3079540A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
US20210255075A1 (en) 2018-03-13 2021-08-19 Amgen Inc. Sequential digestion of polypeptides for mass spectrometric analysis
US20210041453A1 (en) 2018-03-13 2021-02-11 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020009458A1 (ko) * 2018-07-04 2020-01-09 고려대학교 세종산학협력단 옥사졸로퀴놀리논 유도체를 유효성분으로 포함하는 우울증 및 스트레스 관련 질환의 예방 또는 치료용 약학 조성물
CN112469454B (zh) 2018-07-24 2024-01-26 安进公司 用于施用药物的输送装置
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
EP3826699A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Delivery devices for administering drugs
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
EP3829692A1 (en) 2018-07-31 2021-06-09 Amgen Inc. Fluid path assembly for a drug delivery device
MA53724A (fr) 2018-09-24 2021-12-29 Amgen Inc Systèmes et procédés de dosage interventionnel
WO2020068476A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
CN112805048B (zh) 2018-10-02 2023-09-22 安进公司 具有内部力传递的用于药物递送的注射系统
AR116607A1 (es) 2018-10-05 2021-05-26 Amgen Inc Dispositivo de administración de fármacos con indicador de dosis
SG11202101824VA (en) 2018-10-15 2021-03-30 Amgen Inc Platform assembly process for drug delivery device
AR116704A1 (es) 2018-10-15 2021-06-02 Amgen Inc Dispositivo de administración de fármacos con mecanismo de amortiguación
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
MA54048A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
WO2020124008A1 (en) 2018-12-14 2020-06-18 Amgen Inc. System suitability method for use with protein concentration determination by slope
JP7483731B2 (ja) 2019-02-14 2024-05-15 アムジエン・インコーポレーテツド 試料の調製及びその試料のリアルタイムアッセイの実施のためのシステム及び方法
AU2020226619A1 (en) 2019-02-20 2021-08-05 Amgen Inc. Methods of determining protein stability
EP3935396A1 (en) 2019-03-04 2022-01-12 Amgen Inc. In vivo reversibility of high molecular weight species
CA3133459A1 (en) 2019-03-27 2020-10-01 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
MX2021012557A (es) 2019-04-24 2021-11-12 Amgen Inc Conjuntos y metodos de verificacion de esterilizacion de jeringuillas.
TW202110882A (zh) 2019-06-04 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 能結合胸腺基質淋巴細胞生成素的抗體及其應用
MX2021014733A (es) 2019-06-05 2022-04-06 Amgen Inc Metodos de identificacion de atributos de proteinas terapeuticas.
CA3148261A1 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
CN111171150B (zh) * 2020-02-05 2020-12-08 北京智仁美博生物科技有限公司 抗人tslp抗体及其用途
TW202227470A (zh) 2020-09-18 2022-07-16 美商安進公司 處理樣本用於肽作圖分析之方法
JP2023549113A (ja) 2020-11-05 2023-11-22 アムジエン・インコーポレーテツド タンパク質を処理するための材料及び方法
WO2022246055A1 (en) 2021-05-21 2022-11-24 Amgen Inc. Method of optimizing a filling recipe for a drug container
WO2023086793A1 (en) 2021-11-09 2023-05-19 Amgen Inc. Production of therapeutic proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323776C (en) 1998-03-19 2010-04-27 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
ES2317917T3 (es) 2000-06-28 2009-05-01 Amgen Inc. Moleculas de receptor de linfopoyetina estromal timica y sus usos de las mismas.
AU2001271624A1 (en) 2000-06-28 2002-01-08 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
US6890734B2 (en) * 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
NZ533987A (en) * 2002-02-01 2007-04-27 Schering Corp Uses of mammalian cytokine; agonists and antagonists for modulating antigen presenting cell priming of T cells
DE602004016522D1 (de) * 2003-07-18 2008-10-23 Schering Corp Behandlung und diagnose von neoplasien mit tslp (thymic stromal lymphopoietin)
US20050249712A1 (en) 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
EP1793856A2 (en) * 2004-08-20 2007-06-13 Amgen Inc. Methods and compositions for treating allergic inflammation
US20060171943A1 (en) 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
BRPI0706530A2 (pt) * 2006-01-13 2011-03-29 Irm Llc métodos e composições para tratamento de doenças alérgicas
WO2009100324A1 (en) 2008-02-07 2009-08-13 Schering Corporation Engineered anti-tslpr antibodies

Also Published As

Publication number Publication date
AU2008265128A1 (en) 2008-12-24
EA201000006A1 (ru) 2010-10-29
TW200918557A (en) 2009-05-01
US20090074747A1 (en) 2009-03-19
PE20090768A1 (es) 2009-07-09
CL2008001826A1 (es) 2009-02-20
EP2170957A1 (en) 2010-04-07
TN2009000529A1 (en) 2011-03-31
US8101182B2 (en) 2012-01-24
CR11152A (es) 2010-01-20
JP2010530233A (ja) 2010-09-09
AR067045A1 (es) 2009-09-30
KR20100034015A (ko) 2010-03-31
IL202573A0 (en) 2011-08-01
WO2008155365A1 (en) 2008-12-24
BRPI0813725A2 (pt) 2014-12-30
ECSP099812A (es) 2010-01-29
CN102027012A (zh) 2011-04-20
CA2691157A1 (en) 2008-12-24
ZA200908711B (en) 2010-08-25

Similar Documents

Publication Publication Date Title
CO6251325A2 (es) Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20110306A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
AR070346A1 (es) Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos
AR083747A1 (es) Anticuerpos anti-il-23
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
CR20130351A (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina (diviisional 9819)
AR072985A1 (es) Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
NZ717847A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
AR095432A1 (es) Proteínas de unión a antígeno
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20120429A1 (es) Proteinas de enlace de miostatina
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
PE20121361A1 (es) Antagonistas de pcsk9
PE20120414A1 (es) Proteinas biespecificas tetravalentes de union a antigeno
RS54113B1 (en) COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN
PE20120306A1 (es) Anticuerpos anti-egfr y vectores que los codifican

Legal Events

Date Code Title Description
FA Application withdrawn